Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk management decisions in women with BRCA1 and BRCA2 mutations.

American journal of surgery - 1 May 2018

Morgan Rosemary, Brown Audrey, Hamman Kelly Jo, Sampson Jone, Naik Arpana, Massimino Kristen

Abstract excerpt

INTRODUCTION: Pathogenic mutations and variants of uncertain significance (VUS) occur in BRCA1/2 genes. METHODS: Records of women with a pathogenic mutation or VUS in BRCA1/2 treated between 2008 and 2017 were reviewed. RESULTS: One hundred and ten women were included. Mean age was 47. A pathogenic mutation or a VUS in BRCA1/2 was detected in 85 (77%) and 25 (23%) patients, respectively. The rate of risk reducing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Decision Making

Share to Genetic Testing

Share to Mastectomy

Share to Risk Management

Share to Risk Reduction Behavior

Source

Identifiers

PMID: 29499861
DOI: 10.1016/j.amjsurg.2018.02.010

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk management decisions in women with BRCA1 and BRCA2 mutations.PMID 29499861Read ↗

Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.Semantic proximity Read ↗

Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.Semantic proximity Read ↗

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.Semantic proximity Read ↗

Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.Semantic proximity Read ↗

When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.Semantic proximity Read ↗

The clinical management of BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art.Semantic proximity Read ↗

Risk reducing mastectomy in Norwegian BRCA1/2 carriers.Semantic proximity Read ↗

Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers.Semantic proximity Read ↗

Breast cancer surgery in the era of genetic uncertainty: real-world outcomes in BRCA1/2 pathogenic variants and variants of uncertain significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.